Document is current
Any future updates will be listed below
-
Authors
Pan, Qi
Zhai, Xiaoyu
Wang, Haining
Du, Jianling
Shi, Yanxia
Yu, Xuefeng
Yan, Sunjie
Wu, Xiaohong
Li, Hui-hui
Sun, Tao
Guo, Lixin
Zhao, Jun
Fan, Bifa
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06546202 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China: A Retrospective, Database, Multicenter Study (ReTARdant) Protocol
https://doi.org/10.1007/s40122-025-00767-x
-
Funding
Funding for this research was provided by:
Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China.
- License Information
-
More Information
Article History
Received: 2 June 2025
Accepted: 23 July 2025
First Online: 11 August 2025
Declarations
:
: This study was funded by Daiichi Sankyo (China). All authors (Qi Pan, Xiaoyu Zhai, Haining Wang, Jianling Du, Yanxia Shi, Xuefeng Yu, Sunjie Yan, Xiaohong Wu, Hui-hui Li, Tao Sun, Lixin Guo, Jun Zhao, Bifa Fan) declare no other conflict of interest and have nothing to disclose.
: The study will be performed in accordance with the principles stated in the Declaration of Helsinki of 1964 and its later amendments. Ethical approval from leading hospitals was obtained from the China-Japan Friendship Hospital ethics committee (2024-KY-131) and Beijing Cancer Hospital ethics committee (2024YW107); the collaborating hospitals obtained local approval (Supplementary Tables ). As a result of all patient data being collected retrospectively, written informed consent from patients was waived by the ethics committee. The results will be published in academic journals and presented at national and international academic conferences.
: Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.
: Not applicable.
: This is version 1.2 of the protocol, dated December 18, 2024. Data collection is ongoing and expected to be completed by September 2025.
